Interventions
Where each approach stands and the latest research in our collection. Every overview links to its background sources and recent updates; detailed AI reviews are available where completed.
40 tracked topics · AI-written overviews, not expert-reviewed · Recent updates cover the last 30 days.
- Epigenetic clocks
Frontier · 4 collected reports
Epigenetic clocks estimate aspects of biological ageing from chemical patterns on DNA. Some estimates help predict later health outcomes, but they are measurement tools rather than treatments. A clock reading becoming younger is not automatically proof that an intervention prevents disease or extends life; that connection needs validation against outcomes people actually experience. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI-reviewed · not yet expert-reviewed
Read review & sources → - Gene therapy for ageing
Frontier · 4 collected reports
Gene therapy changes gene activity or the properties of cells to treat a particular condition. Approved applications exist for specific diseases, but their success cannot be transferred automatically to experimental ageing targets. For longevity, the relevant questions are which tissue and pathway are changed, whether people gain meaningful health benefits, and what risks persist after treatment. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - Klotho
Frontier · 5 collected reports
Klotho is a protein studied for links with ageing and brain function. Giving it to aged rhesus monkeys improved performance on a memory task in a small experimental study. That is an animal cognition result, not evidence of human life extension; clinical benefit, delivery and safety in people are separate questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - Partial cellular reprogramming
Frontier · 1 collected reports
Partial reprogramming tries to restore aspects of youthful cell function by altering gene activity. A landmark mouse study restored aspects of vision, providing evidence that some tissue changes can be modified experimentally. Restoring function in one animal tissue does not establish whole-body rejuvenation in humans; control, delivery and long-term safety are critical translation questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - Senolytics
Frontier · 43 collected reports
Senolytics aim to remove cells that have entered a persistent damaged state. Human testing is underway, but findings are still limited: an NIA-supported trial in older women found only limited bone-health benefits compared with controls. A promising cellular mechanism should therefore be distinguished from demonstrated prevention of age-related disease or longer life in people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 23, 2026: “SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial”. Its implications have not yet been summarized in a source-checked review. Read update ↗
AI-reviewed · not yet expert-reviewed
Read review & sources → - Stem cell therapy
Frontier · 6 collected reports
Cell therapies have legitimate, specific medical applications, but that does not validate broadly marketed anti-ageing infusions. The FDA warns that unapproved regenerative products can cause serious harm. Each product and indication needs its own clinical evidence; calling something a stem-cell treatment is not evidence of rejuvenation, effectiveness or safety. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI-reviewed · not yet expert-reviewed
Read review & sources → - Therapeutic plasma exchange
Frontier · 0 collected reports
Plasma exchange removes and replaces the liquid part of blood. A randomized human study reported changes in biological-age measurements, attracting interest in ageing applications. Those measurements are indirect endpoints: the study does not establish longer life or prevention of age-related illness, and the burdens and risks of a medical procedure matter alongside biomarker changes. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research →
| Intervention | Current state & recent changes | Research & review |
|---|---|---|
| Epigenetic clocks Frontier | Epigenetic clocks estimate aspects of biological ageing from chemical patterns on DNA. Some estimates help predict later health outcomes, but they are measurement tools rather than treatments. A clock reading becoming younger is not automatically proof that an intervention prevents disease or extends life; that connection needs validation against outcomes people actually experience. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Read review & sources → | 4 collected reports AI-reviewed · not yet expert-reviewed Oct 22, 2026 |
| Gene therapy for ageing Frontier | Gene therapy changes gene activity or the properties of cells to treat a particular condition. Approved applications exist for specific diseases, but their success cannot be transferred automatically to experimental ageing targets. For longevity, the relevant questions are which tissue and pathway are changed, whether people gain meaningful health benefits, and what risks persist after treatment. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 4 collected reports AI review not yet available |
| Klotho Frontier | Klotho is a protein studied for links with ageing and brain function. Giving it to aged rhesus monkeys improved performance on a memory task in a small experimental study. That is an animal cognition result, not evidence of human life extension; clinical benefit, delivery and safety in people are separate questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 5 collected reports AI review not yet available |
| Partial cellular reprogramming Frontier | Partial reprogramming tries to restore aspects of youthful cell function by altering gene activity. A landmark mouse study restored aspects of vision, providing evidence that some tissue changes can be modified experimentally. Restoring function in one animal tissue does not establish whole-body rejuvenation in humans; control, delivery and long-term safety are critical translation questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 1 collected reports AI review not yet available |
| Senolytics Frontier | Senolytics aim to remove cells that have entered a persistent damaged state. Human testing is underway, but findings are still limited: an NIA-supported trial in older women found only limited bone-health benefits compared with controls. A promising cellular mechanism should therefore be distinguished from demonstrated prevention of age-related disease or longer life in people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 23, 2026: “SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial”. Its implications have not yet been summarized in a source-checked review. Read update ↗ Read review & sources → | 43 collected reports AI-reviewed · not yet expert-reviewed Sep 26, 2026 |
| Stem cell therapy Frontier | Cell therapies have legitimate, specific medical applications, but that does not validate broadly marketed anti-ageing infusions. The FDA warns that unapproved regenerative products can cause serious harm. Each product and indication needs its own clinical evidence; calling something a stem-cell treatment is not evidence of rejuvenation, effectiveness or safety. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Read review & sources → | 6 collected reports AI-reviewed · not yet expert-reviewed Sep 26, 2026 |
| Therapeutic plasma exchange Frontier | Plasma exchange removes and replaces the liquid part of blood. A randomized human study reported changes in biological-age measurements, attracting interest in ageing applications. Those measurements are indirect endpoints: the study does not establish longer life or prevention of age-related illness, and the burdens and risks of a medical procedure matter alongside biomarker changes. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 0 collected reports AI review not yet available |